Nice Little Read Here! 
HRTX...
This growth stock is set to sail. Or YACHT!
George Budwell (Heron Therapeutics): If you're looking for ways to grow your money at an unusually high rate, the mid-cap biotech Heron Therapeutics should be on your radar. After two positive late-stage trials for its experimental pain medication HTX-011 last month, the company is now set to have three products on the market within the next 12 months. As a result, Heron's top line is forecast to grow by an astounding 163% next year.
The best part about this story is that HTX-011 could end up becoming a major new tool to help replace opioid use in the acute-pain setting. If so, this experimental pain med should generate some truly eye-popping sales figures in the years ahead -- especially since most of the drug's direct competitors have already failed in clinical trials over the past two years. The bottom line is that Heron's HTX-011 and Pacira Pharmaceuticals' Exparel should end up gobbling up the lion's share of this multibillion-dollar drug market.
Beyond the biotech's improving fundamentals, there's also a strong chance that a top biopharma will soon make a play for Heron's analgesic and antiemetic portfolio.
Pfizer, after all, is close to losing exclusivity for its megablockbuster pain med Lyrica, and this biopharma giant is absolutely flush with cash at the moment. When it comes to making deals, Pfizer is also known to prefer companies with either late-stage assets or drugs already on the market;
Heron arguably checks all the boxes that Pfizer looks for in a midsized acquisition. 
Heron is a solid growth play that's been greatly de-risked by the positive late-stage results for HTX-011 -- arguably making it worth a look by investors on the hunt for above-average returns on capital.
https://finance.yahoo.com/news/don-a...013200785.html